Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: May 2010

11 - Effects of obesity on anesthetic agents

from Section 3 - Intra-operative management

Summary

This chapter summarizes current knowledge about changes in pulmonary physiology associated with obesity. It describes the pathophysiology of obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS). In obese individuals with OSA, increased soft tissue deposition in the pharyngeal region and tongue contributes to a decreased upper airway size. The polysomnography (PSG) remains the standard for diagnosis and assessment of the severity of OSA. Expert consensus concluded that the degree of peri-operative risk for patients with OSA depends on the severity of the OSA and the type of surgery. Obesity hypoventilation syndrome is a diagnosis of exclusion and requires the absence of other reasons for chronic hypoventilation such as chronic lung or neuromuscular disease. Additional treatment options for OHS similar to those for OSA are available including pharmacotherapy. The significant potential cardio-pulmonary co-morbidities present in OHS patients mandate a high index of suspicion to identify these patients preoperatively.

References

1. PriceHL. A dynamic concept of the distribution of thiopental in the human body. Anesthesiology 1960; 21: 40–5.
2. WadaDR, BjorkmanS, EblingWF, et al. Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 1997; 87: 884–99.
3. BjorkmanS, WadaDR, StanskiDR. Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients. Anesthesiology 1998; 88: 657–67.
4. BjorkmanS, WadaDR, BerlingBM, BenoniG.Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90: 1226–41.
5. HanPY, DuffullSB, KirkpatrickCM, GreenB.Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505–8.
6. CollisT, DevereuxRB, RomanMJ, et al. Relations of stroke volume and CO to body composition: the strong heart study. Circulation 2001; 103: 820–5.
7. MorettoM, KupskiC, MottinCC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg 2003; 13: 622–4.
8. ServinF, FarinottiR, HabererJP, DesmontsJM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657–65.
9. JamesW.Research on Obesity. London: Her Majesty's Stationery Office, 1976.
10. JanmahasatianS, DuffullSB, AshS, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051–65.
11. JungD, MayersohnM, PerrierD, et al. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 1982; 56: 269–74.
12. UptonRN, LudbrookGL, GrantC, MartinezAM. CO is a determinant of the initial concentrations of propofol after short-infusion administration. Anesth Analg 1999; 89: 545–52.
13. UptonRN, LudbrookG.A physiologically based, recirculatory model of the kinetics and dynamics of propofol in man. Anesthesiology 2005; 103: 344–52.
14. BarannM, LindenI, WittenS, UrbanBW. Molecular actions of propofol on human 5-HT3A receptors: enhancement as well as inhibition by closely related phenol derivatives. Anesth Analg 2008; 106: 846–57.
15. FeldJM, HoffmanWE, StechertMM, et al. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth 2006; 18: 24–8.
16. TufanogullariB, WhitePF, PeixotoMP, et al. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg 2008; 106: 1741–8.
17. ShibutaniK, InchiosaMA, Jr., SawadaK, BairamianM.Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight (“pharmacokinetic mass”). Anesthesiology 2004; 101: 603–13.
18. SlepchenkoG, SimonN, GoubauxB, et al. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology 2003; 98: 65–73.
19. EganTD, HuizingaB, GuptaSK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562–73.
20. De BaerdemaekerLE, JacobsS, PattynP, et al. Influence of intraoperative opioid on postoperative pain and pulmonary function after laparoscopic gastric banding: remifentanil TCI vs sufentanil TCI in morbid obesity. Br J Anaesth 2007; 99: 404–11.
21. LemmensHJ, SaidmanLJ, EgerEI, 2nd, LasterMJ. Obesity modestly affects inhaled anesthetic kinetics in humans. Anesth Analg 2008; 107: 1864–70.
22. LesserGT, DeutschS.Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 1967; 23: 621–30.
23. YasudaN, LockhartSH, EgerEI, 2nd, et al. Kinetics of desflurane, isoflurane, and halothane in humans. Anesthesiology 1991; 74: 489–98.
24. CarpenterRL, EgerEI, 2nd, JohnsonBH, et al. Pharmacokinetics of inhaled anesthetics in humans: measurements during and after the simultaneous administration of enflurane, halothane, isoflurane, methoxyflurane, and nitrous oxide. Anesth Analg 1986; 65: 575–82.
25. TorriG, CasatiA, AlbertinA, et al. Randomized comparison of isoflurane and sevoflurane for laparoscopic gastric banding in morbidly obese patients. J Clin Anesth 2001; 13: 565–70.
26. StrumEM, SzenohradszkiJ, KaufmanWA, et al. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: a prospective, randomized study. Anesth Analg 2004; 99: 1848–53.
27. De BaerdemaekerLE, StruysMM, JacobsS, et al. Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane using an ‘inhalation bolus’ technique. Br J Anaesth 2003; 91: 638–50.
28. ArainSR, BarthCD, ShankarH, EbertTJ. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. J Clin Anesth 2005; 17: 413–9.
29. VallejoMC, SahN, PhelpsAL, et al. Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. J Clin Anesth 2007; 19: 3–8.
30. La CollaL, AlbertinA, La CollaG, ManganoA.Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. Br J Anaesth 2007; 99: 353–8.
31. CasatiA, MarchettiC, SpreaficoE, MamoD.Effects of obesity on wash-in and wash-out kinetics of sevoflurane. Eur J Anaesthesiol 2004; 21: 243–5.
32. TorriG, CasatiA, ComottiL, et al. Wash-in and wash-out curves of sevoflurane and isoflurane in morbidly obese patients. Minerva Anestesiol 2002; 68: 523–7.
33. BentleyJB, BorelJD, VaughanRW, GandolfiAJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. Anesthesiology 1982; 57: 48–9.
34. LemmensHJ, BrodskyJB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102: 438–42.
35. PuhringerFK, KellerC, KleinsasserA, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16: 507–10.
36. LeykinY, PellisT, LuccaM, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004; 99: 1086–9.
37. SchwartzAE, MatteoRS, OrnsteinE, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74: 515–8.
38. LeykinY, PellisT, LuccaM, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99: 1090–4.
39. Kirkegaard-NielsenH, Helbo-HansenHS, LindholmP, et al. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Anesth Analg 1996; 83: 1076–80.
40. TsuedaK, WarrenJE, McCaffertyLA, NagleJP. Pancuronium bromide requirement during anesthesia for the morbidly obese. Anesthesiology 1978; 48: 438–9.
41. SuzukiT, MasakiG, OgawaS.Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth 2006; 97: 160–3.
42. Kirkegaard-NielsenH, LindholmP, PetersenHS, SeverinsenIK. Antagonism of atracurium-induced block in obese patients. Can J Anaesth 1998; 45: 39–41.